Insmed Management

Management criteria checks 2/4

Insmed's CEO is Will Lewis, appointed in Sep 2012, has a tenure of 11.67 years. total yearly compensation is $10.41M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth €9.97M. The average tenure of the management team and the board of directors is 4.5 years and 10 years respectively.

Key information

Will Lewis

Chief executive officer

US$10.4m

Total compensation

CEO salary percentage	7.5%
CEO tenure	11.7yrs
CEO ownership	0.3%
Management average tenure	4.5yrs
Board average tenure	10yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Will Lewis's remuneration changed compared to Insmed's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$10m	US$780k	-US$750m
Sep 30 2023	n/a	n/a	-US$724m
Jun 30 2023	n/a	n/a	-US$696m
Mar 31 2023	n/a	n/a	-US$547m
Dec 31 2022	US$8m	US$735k	-US$482m
Sep 30 2022	n/a	n/a	-US$434m
Jun 30 2022	n/a	n/a	-US$416m
Mar 31 2022	n/a	n/a	-US$438m
Dec 31 2021	US$7m	US$710k	-US$435m
Sep 30 2021	n/a	n/a	-US$424m
Jun 30 2021	n/a	n/a	-US$375m
Mar 31 2021	n/a	n/a	-US$319m
Dec 31 2020	US$6m	US$660k	-US$294m
Sep 30 2020	n/a	n/a	-US$245m
Jun 30 2020	n/a	n/a	-US$242m
Mar 31 2020	n/a	n/a	-US$247m
Dec 31 2019	US$7m	US$641k	-US$254m
Sep 30 2019	n/a	n/a	-US$293m
Jun 30 2019	n/a	n/a	-US$320m
Mar 31 2019	n/a	n/a	-US$330m
Dec 31 2018	US$6m	US$610k	-US$324m
Sep 30 2018	n/a	n/a	-US$298m
Jun 30 2018	n/a	n/a	-US$256m
Mar 31 2018	n/a	n/a	-US$224m
Dec 31 2017	US$4m	US$567k	-US$193m

Compensation vs Market: Will's total compensation ($USD10.41M) is above average for companies of similar size in the German market ($USD2.58M).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.

CEO

Will Lewis (54 yo)

11.7yrs

Tenure

US$10,411,260

Compensation

Mr. William H. Lewis, also known as Will, J.D. M.B.A. serves as Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January, 2024. He has been Chief Executive Officer and President at I...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Lewis	President	11.7yrs	US$10.41m	0.28% $ 10.0m
Sara Bonstein	Chief Financial Officer	4.3yrs	US$4.56m	0.0035% $ 124.6k
Roger Adsett	Chief Operating Officer	4.5yrs	US$4.01m	0.040% $ 1.4m
John Wise	Chief Commercial Officer	4.5yrs	US$3.89m	0.025% $ 876.4k
Martina Flammer	Chief Medical Officer	4.4yrs	US$4.22m	0.0041% $ 145.2k
Brian Kaspar	Chief Scientific Officer	no data	no data	no data
Eleanor Barisser	Associate Director of Investor Relations	no data	no data	no data
Michael Smith	Chief Legal Officer & Corporate Secretary	2.8yrs	no data	0.058% $ 2.1m
Mandy Fahey	Executive Director of Corporate Communications	no data	no data	no data
S. Schaeffer	Chief People Strategy Officer	11.3yrs	US$2.66m	0.025% $ 876.7k
Eugene Sullivan	Chief Product Strategy Officer	7yrs	US$1.69m	no data
Neil Hughes	GM & Head of Europe	4.9yrs	no data	no data

4.5yrs

Average Tenure

54yo

Average Age

Experienced Management: IM8N's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
William Lewis	President	11.7yrs	US$10.41m	0.28% $ 10.0m
David W. McGirr	Independent Director	10.6yrs	US$320.00k	0.049% $ 1.7m
Melvin Sharoky	Independent Director	23yrs	US$312.50k	0.22% $ 7.7m
Alfred Altomari	Independent Director	11.8yrs	US$320.00k	0.029% $ 1.0m
David Brennan	Lead Independent Director	10yrs	US$345.00k	0.064% $ 2.3m
Clarissa Desjardins	Independent Director	4.5yrs	US$315.00k	0.024% $ 848.4k
Elizabeth Anderson	Independent Director	5.5yrs	US$310.00k	0.028% $ 1.0m
Leo Lee	Independent Director	6yrs	US$315.00k	0.066% $ 2.3m
Carol Schafer	Independent Director	4.1yrs	US$315.00k	0.021% $ 760.6k

10.0yrs

Average Tenure

64yo

Average Age

Experienced Board: IM8N's board of directors are seasoned and experienced ( 10 years average tenure).

Insmed Management

Management criteria checks 2/4

Key information

Recent management updates

Insmed Incorporated, Annual General Meeting, May 13, 2024

Senior VP recently sold €63k worth of stock

President recently sold €132k worth of stock

Insufficient new directors

Chief Operating Officer recently sold €217k worth of stock

Chief Operating Officer recently sold €217k worth of stock

Recent updates

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Full year 2023 earnings released: US$5.34 loss per share (vs US$3.91 loss in FY 2022)

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: US$1.11 loss per share (vs US$1.09 loss in 3Q 2022)

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Second quarter 2023 earnings released: US$1.78 loss per share (vs US$0.80 loss in 2Q 2022)

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold €63k worth of stock

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

First quarter 2023 earnings released: US$1.17 loss per share (vs US$0.80 loss in 1Q 2022)

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

President recently sold €132k worth of stock

Insufficient new directors

Chief Operating Officer recently sold €217k worth of stock

Chief Operating Officer recently sold €217k worth of stock

Now 22% undervalued after recent price drop

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$1.09 loss per share (vs US$0.96 loss in 3Q 2021)

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$1.07 loss in 2Q 2021)

Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022

Insmed Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Insmed Incorporated Names Drayton Wise as Chief Commercial Officer

Independent Director recently bought €326k worth of stock

First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.89 loss in 1Q 2021)

Insmed Incorporated to Report Q1, 2022 Results on May 05, 2022

Insmed Incorporated, Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Insmed Incorporated Provides Earnings Guidance for the Full Year 2022

Insmed Incorporated to Report Q4, 2021 Results on Feb 17, 2022

President recently sold €63k worth of stock

Independent Director recently bought €370k worth of stock

Third quarter 2021 earnings released: US$0.96 loss per share (vs US$0.63 loss in 3Q 2020)

High number of new directors

Insmed Incorporated Unable to Provides Revenue Guidance Due to Covid

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $250 million.

First quarter 2021 earnings released: US$0.89 loss per share (vs US$0.74 loss in 1Q 2020)

Independent Director recently bought €83k worth of stock

Revenue misses expectations

Full year 2020 earnings released: US$3.01 loss per share (vs US$3.01 loss in FY 2019)

Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)

Insmed Incorporated to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €36.60

New 90-day high: €34.40

Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

Insmed Incorporated Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Independent Director recently sold €264k worth of stock

New 90-day high: €33.40

Insmed Incorporated Receives Priority Medicines (Prime) Designation from European Medicines Agency for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

New 90-day high: €29.80

Independent Director recently sold €518k worth of stock

New 90-day high: €28.60

New 90-day high - €27.00

First half earnings released